日本高潮视频在线观看-亚洲中文字幕永不卡-精品亚洲一区二区三区-伦理片夜夜躁狠狠躁日日躁-日本最新免费不卡二区-国产精品口爆一区二区三区-av一区二区三区高清-大鸡巴疯狂抽插小穴视频-日韩中文国产在线观看免费视频

Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Lactobacillus johnsonii Peptidyl-tRNA hydrolase (pth) CSB-YP751683LAW
CSB-EP751683LAW
CSB-BP751683LAW
CSB-MP751683LAW
CSB-EP751683LAW-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Lactobacillus johnsonii UDP-N-acetylglucosamine 1-carboxyvinyltransferase (murA) CSB-YP751684LAW
CSB-EP751684LAW
CSB-BP751684LAW
CSB-MP751684LAW
CSB-EP751684LAW-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Lactobacillus johnsonii Probable potassium transport system protein kup 2 (kup2), partial CSB-YP751685LAW
CSB-EP751685LAW
CSB-BP751685LAW
CSB-MP751685LAW
CSB-EP751685LAW-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Lactobacillus johnsonii UPF0337 protein LJ_0034.1 (LJ_0034.1) CSB-YP751686LAW
CSB-EP751686LAW
CSB-BP751686LAW
CSB-MP751686LAW
CSB-EP751686LAW-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Nanoarchaeum equitans Elongation factor 2 (fusA), partial CSB-YP751687NAQ
CSB-EP751687NAQ
CSB-BP751687NAQ
CSB-MP751687NAQ
CSB-EP751687NAQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Nanoarchaeum equitans 30S ribosomal protein S17e (rps17e) CSB-YP751688NAQ
CSB-EP751688NAQ
CSB-BP751688NAQ
CSB-MP751688NAQ
CSB-EP751688NAQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Nanoarchaeum equitans 30S ribosomal protein S12P (rps12p) CSB-YP751689NAQ
CSB-EP751689NAQ
CSB-BP751689NAQ
CSB-MP751689NAQ
CSB-EP751689NAQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Nanoarchaeum equitans DNA-directed RNA polymerase subunit L (rpoL) CSB-YP751690NAQ
CSB-EP751690NAQ
CSB-BP751690NAQ
CSB-MP751690NAQ
CSB-EP751690NAQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Nanoarchaeum equitans DNA polymerase sliding clamp (pcn) CSB-YP751691NAQ
CSB-EP751691NAQ
CSB-BP751691NAQ
CSB-MP751691NAQ
CSB-EP751691NAQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Nanoarchaeum equitans Methionine--tRNA ligase (metG), partial CSB-YP751692NAQ
CSB-EP751692NAQ
CSB-BP751692NAQ
CSB-MP751692NAQ
CSB-EP751692NAQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Nanoarchaeum equitans 50S ribosomal protein L37Ae (rpl37ae) CSB-YP751693NAQ
CSB-EP751693NAQ
CSB-BP751693NAQ
CSB-MP751693NAQ
CSB-EP751693NAQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Nanoarchaeum equitans Fibrillarin-like rRNA/tRNA 2'-O-methyltransferase (flpA) CSB-YP751694NAQ
CSB-EP751694NAQ
CSB-BP751694NAQ
CSB-MP751694NAQ
CSB-EP751694NAQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Nanoarchaeum equitans 30S ribosomal protein S4P (rps4p) CSB-YP751695NAQ
CSB-EP751695NAQ
CSB-BP751695NAQ
CSB-MP751695NAQ
CSB-EP751695NAQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Bacillus cereus UPF0751 protein BCE_A0020 (BCE_A0020) CSB-YP751696BQN
CSB-EP751696BQN
CSB-BP751696BQN
CSB-MP751696BQN
CSB-EP751696BQN-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant sn-glycerol-3-phosphate import ATP-binding protein UgpC (ugpC) CSB-YP751697YAS
CSB-EP751697YAS
CSB-BP751697YAS
CSB-MP751697YAS
CSB-EP751697YAS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant UPF0756 membrane protein YPO3057/y1423/YP_2679 (YPO3057, y1423, YP_2679), partial CSB-YP751698YAS1
CSB-EP751698YAS1
CSB-BP751698YAS1
CSB-MP751698YAS1
CSB-EP751698YAS1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Divalent-cation tolerance protein CutA (cutA) CSB-YP751699YAS
CSB-EP751699YAS
CSB-BP751699YAS
CSB-MP751699YAS
CSB-EP751699YAS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ashbya gossypii mRNA-decapping enzyme subunit 1 (DCP1) CSB-YP751700DOT
CSB-EP751700DOT
CSB-BP751700DOT
CSB-MP751700DOT
CSB-EP751700DOT-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ashbya gossypii Ubiquitin-conjugating enzyme E2 6 (UBC6), partial CSB-YP751701DOT
CSB-EP751701DOT
CSB-BP751701DOT
CSB-MP751701DOT
CSB-EP751701DOT-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ashbya gossypii Enhancer of translation termination 1 (ETT1) CSB-YP751702DOT
CSB-EP751702DOT
CSB-BP751702DOT
CSB-MP751702DOT
CSB-EP751702DOT-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長度(全長或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://m.bdspa.cn/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>



×